In addition, three glucose metabolism-related genes (SERPINE1, VCAN, and TFPI2) may be the potential targets for the immunotherapy of patients with NAFLD-hepatocellular carcinoma. Here, TFPI2 is linked to metabolic dysfunction-associated steatotic liver disease.